| Name | Title | Contact Details |
|---|
Overlook House is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Scinexa Medical Education Group is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cato Research is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HealthEast Care System is a community-focused, nonprofit healthcare system that provides a full spectrum of HealthEast Care System is a community-focused, nonprofit healthcare system that provides a full spectrum of family health services. Hospitals include St. Joseph`s Hospital, St. John`s Hospital, Woodwinds Health Campus and Bethesda Rehabilitation Hospital. Other services include hospitals, physician clinics, senior care centers, rehabilitation facilities, hospice, home care, outpatient surgery centers, and a variety of other health facilities and programs. HealthEast has approximately 7,500 employees and has more than 1,300 physicians on staff. Locally owned and operated, HealthEast is the largest health care provider in the Twin Cities` East Metro area.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.